• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Translating the role of PARP inhibitors in triple-negative breast cancer.

作者信息

Beniey Michèle, Haque Takrima, Hassan Saima

机构信息

Division of Surgical Oncology, Department of Surgery, Centre Hospitalier de l'Université de Montréal (CHUM); Université de Montréal; Institut du cancer de Montréal and Centre de Recherche du CHUM (CRCHUM), Montreal, Quebec, Canada.

出版信息

Oncoscience. 2019 Jan 31;6(1-2):287-288. doi: 10.18632/oncoscience.474. eCollection 2019 Jan.

DOI:10.18632/oncoscience.474
PMID:30800714
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6382255/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e92c/6382255/e087ec8a7f2f/oncoscience-06-287-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e92c/6382255/e087ec8a7f2f/oncoscience-06-287-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e92c/6382255/e087ec8a7f2f/oncoscience-06-287-g001.jpg

相似文献

1
Translating the role of PARP inhibitors in triple-negative breast cancer.解读聚（ADP-核糖）聚合酶抑制剂在三阴性乳腺癌中的作用
Oncoscience. 2019 Jan 31;6(1-2):287-288. doi: 10.18632/oncoscience.474. eCollection 2019 Jan.
2
Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor.采用抗 EGFR 导向放射免疫治疗联合放射增敏化疗和 PARP 抑制剂治疗三阴性乳腺癌。
J Nucl Med. 2013 Jun;54(6):913-21. doi: 10.2967/jnumed.112.111534. Epub 2013 Apr 5.
3
PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.聚腺苷二磷酸核糖聚合酶抑制剂在三阴性乳腺癌治疗中的应用。
Clin Pharmacokinet. 2018 Apr;57(4):427-437. doi: 10.1007/s40262-017-0587-4.
4
53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.53BP1缺失导致ATM缺陷型乳腺癌细胞对PARP抑制剂产生耐药性。
BMC Cancer. 2016 Sep 9;16(1):725. doi: 10.1186/s12885-016-2754-7.
5
The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality.聚腺苷二磷酸核糖聚合酶抑制剂在三阴性乳腺癌中的作用：揭示广泛的合成致死性。
Cancer Treat Rev. 2018 Jun;67:34-44. doi: 10.1016/j.ctrv.2018.04.010. Epub 2018 May 2.
6
Metformin reverses PARP inhibitors-induced epithelial-mesenchymal transition and PD-L1 upregulation in triple-negative breast cancer.二甲双胍可逆转三阴性乳腺癌中PARP抑制剂诱导的上皮-间质转化及PD-L1上调。
Am J Cancer Res. 2019 Apr 1;9(4):800-815. eCollection 2019.
7
RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer.RAD51 介导三阴性乳腺癌肿瘤干细胞对 PARP 抑制剂的耐药性。
Clin Cancer Res. 2017 Jan 15;23(2):514-522. doi: 10.1158/1078-0432.CCR-15-1348. Epub 2016 Dec 29.
8
CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.CDK12抑制可逆转三阴性乳腺癌BRCA野生型和突变模型中的原发性和获得性PARP抑制剂耐药性。
Cell Rep. 2016 Nov 22;17(9):2367-2381. doi: 10.1016/j.celrep.2016.10.077.
9
Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.应用新一代测序技术重新定义三阴性乳腺癌的 BRCA 状态。
Cancer Sci. 2020 Apr;111(4):1375-1384. doi: 10.1111/cas.14313. Epub 2020 Feb 19.
10
BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.BRCA 基因突变与三阴性乳腺癌中的聚（ADP-核糖）聚合酶抑制剂。
Adv Exp Med Biol. 2017;1026:271-286. doi: 10.1007/978-981-10-6020-5_13.

引用本文的文献

1
Identification and Characterization of Novel Inhibitors of Human Poly(ADP-Ribose) Polymerase-1.新型人类聚（ADP - 核糖）聚合酶 -1抑制剂的鉴定与表征
Molecules. 2025 Jun 25;30(13):2728. doi: 10.3390/molecules30132728.
2
Part II: consensus statements and expert recommendations for BRCA-associated breast cancer in the Asia-Pacific region: clinical management.第二部分：亚太地区BRCA相关乳腺癌的共识声明与专家建议：临床管理
Front Oncol. 2025 Jun 23;15:1507840. doi: 10.3389/fonc.2025.1507840. eCollection 2025.
3
Sequential targeting of PARP with carboplatin inhibits primary tumour growth and distant metastasis in triple-negative breast cancer.

本文引用的文献

1
Advances in the use of PARP inhibitor therapy for breast cancer.PARP抑制剂治疗乳腺癌的应用进展。
Drugs Context. 2018 Aug 8;7:212540. doi: 10.7573/dic.212540. eCollection 2018.
2
A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.异种移植模型中存在异质性的乳腺癌患者群体，表明 PARP 抑制剂在 BRCA1/2 野生型肿瘤中有广泛的活性。
Clin Cancer Res. 2017 Nov 1;23(21):6468-6477. doi: 10.1158/1078-0432.CCR-17-0615.
3
Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast Cancer.
卡铂序贯靶向聚腺苷二磷酸核糖聚合酶抑制三阴性乳腺癌的原发肿瘤生长和远处转移。
Br J Cancer. 2023 May;128(10):1964-1975. doi: 10.1038/s41416-023-02226-w. Epub 2023 Mar 20.
4
Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates.用靶向Trop2的抗体药物偶联物揭示三阴性乳腺癌
Am J Cancer Res. 2022 Apr 15;12(4):1671-1685. eCollection 2022.
5
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer.在晚期三阴性乳腺癌患者中进行的berzosertib与顺铂的1b期研究。
NPJ Breast Cancer. 2022 Apr 7;8(1):45. doi: 10.1038/s41523-022-00406-0.
6
Transcribed Ultraconserved Regions Are Associated with Clinicopathological Features in Breast Cancer.转录超保守区与乳腺癌的临床病理特征相关。
Biomolecules. 2022 Jan 26;12(2):214. doi: 10.3390/biom12020214.
7
Targeted EV to Deliver Chemotherapy to Treat Triple-Negative Breast Cancers.靶向细胞外囊泡递送化疗药物治疗三阴性乳腺癌。
Pharmaceutics. 2022 Jan 7;14(1):146. doi: 10.3390/pharmaceutics14010146.
8
Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study.用于三阴性乳腺癌治疗的俄歇发射体共轭聚（ADP-核糖）聚合酶抑制剂：一项体外比较研究
Cancers (Basel). 2022 Jan 4;14(1):230. doi: 10.3390/cancers14010230.
9
Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer.扩大聚（ADP-核糖）聚合酶（PARP）抑制剂在三阴性乳腺癌中作为单一疗法及联合疗法的应用
Pharmaceuticals (Basel). 2021 Dec 6;14(12):1270. doi: 10.3390/ph14121270.
10
A novel lncRNA derived from an ultraconserved region: lnc-, a potential biomarker in luminal A breast cancer.一种新型来自超保守区域的 lncRNA：lnc-，在腔 A 型乳腺癌中的潜在生物标志物。
RNA Biol. 2021 Oct 15;18(sup1):416-429. doi: 10.1080/15476286.2021.1952757. Epub 2021 Aug 13.
与三阴性乳腺癌中 53BP1 对 PARP 抑制反应相关的途径富集基因特征。
Mol Cancer Ther. 2017 Dec;16(12):2892-2901. doi: 10.1158/1535-7163.MCT-17-0170. Epub 2017 Sep 27.
4
A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds.一个保留肿瘤内异质性以筛选抗癌化合物的乳腺癌外植体生物样本库。
Cell. 2016 Sep 22;167(1):260-274.e22. doi: 10.1016/j.cell.2016.08.041. Epub 2016 Sep 15.
5
An update on PARP inhibitors--moving to the adjuvant setting.PARP 抑制剂的最新进展——迈向辅助治疗领域。
Nat Rev Clin Oncol. 2015 Jan;12(1):27-41. doi: 10.1038/nrclinonc.2014.163. Epub 2014 Oct 7.
6
Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib.基于跨平台通路分析鉴定出对 PARP 抑制剂奥拉帕利应答的标志物。
Breast Cancer Res Treat. 2012 Sep;135(2):505-17. doi: 10.1007/s10549-012-2188-0. Epub 2012 Aug 9.
7
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.奥拉帕利治疗复发性高级别浆液性或低分化卵巢癌或三阴性乳腺癌患者的疗效：一项多中心、开放标签、非随机的 2 期临床试验。
Lancet Oncol. 2011 Sep;12(9):852-61. doi: 10.1016/S1470-2045(11)70214-5. Epub 2011 Aug 19.
8
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.鉴定人类三阴性乳腺癌亚型和临床前模型以选择靶向治疗药物。
J Clin Invest. 2011 Jul;121(7):2750-67. doi: 10.1172/JCI45014.